Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors

M Del Re, Ron van Schaik, S Fogli, Ron Mathijssen, F Cucchiara, A Capuano, C Scavone, Guido Jenster, R Danesi

Research output: Contribution to journalArticleAcademic

8 Citations (Scopus)

Abstract

Monoclonal antibodies that inhibit the programmed cell death protein 1 axis (anti-PD-1/PD-L1) are part of a new pharmacological strategy aimed at reinforcing the immune response to cancer. Despite the success in several cancer types, a significant percentage of patients do not benefit from treatment with these drugs due to intrinsic or acquired resistance or the occurrence of immune-related adverse reactions. Assessment of PD-L1 expression in tumor tissues is currently used to predict drug response in the clinics; however, there is a growing interest in identifying blood-based biomarkers that, owing to the minimally-invasive nature, can allow a dynamic monitoring of drug response in daily clinical practice. In the current review article, we discuss whether the assessment of PD-L1 mRNA and protein levels in circulating extracellular vesicles may have the potential to predict the likelihood of tumor response to anti-PD-1/PD-L1 antibodies.

Original languageEnglish
Article number188463
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1875
Issue number1
DOIs
Publication statusPublished - 2021

Fingerprint

Dive into the research topics of 'Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors'. Together they form a unique fingerprint.

Cite this